Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MDS Nordion

This article was originally published in The Gray Sheet

Executive Summary

Radioisotope technology firm plans to roll out by late spring its TheraSphere non-surgical outpatient therapy for the approximately 4,000 annual U.S. cases of inoperable hepatocellular carcinoma following the firm's Dec. 10 receipt of a humanitarian device exemption approval. TheraSphere, which consists of 20-30 um glass beads containing yttrium-90, lodges in tumor vasculature, reducing exposure of healthy tissue to radiation. The product offers advantages over traditional therapies like transarterial chemoembolization, including shorter hospital stays and fewer side effects, the firm claims
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel